Clinical Trials in Boston

Showing 2581-2600 of 15,299 trials

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

NCT01696435

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or fish oil: 1) reduces risk of clinical depressive syndrome, 2) yields better mood scores over time, compared to placebo.

DepressionDepressive SymptomsMood

Brigham and Women's Hospital18,353 participantsStarted Jul 2010

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects

NCT02818699

The purpose of this clinical study is to determine the effect and safety of long-term intake of enzymatically modified isoquercitrin (EMIQ), a natural plant product on body fat loss in obese and overweight individuals.

OverweightObese

Tufts University65 participantsStarted Aug 2016

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

NCT05477147

Multi-center, international, non-randomized clinical trial evaluating the use of Volta's VX1 algorithm as used in combination with repeat catheter ablation after AF recurrence after previous catheter ablation.

Atrial Fibrillation

Volta Medical96 participantsStarted Mar 2023

Birmingham, Alabama, United States • Jonesboro, Arkansas, United States • Jacksonville, Florida, United States +16 more locations

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects

Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

Find Trials by Condition in Boston

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

A Extension Study of Udenafil in Adolescents

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Advanced Fetal Imaging - Phase II

Cognitive Behavior Therapy (CBT)-Based Group Intervention to Reduce Inflammation in Older People With HIV

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)